SCHEMBL790315

SCHEMBL790315

CCOC(=O)c1csc(Nc2ccc(OC)cc2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.64
GAA P10253 3/20 0.64
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
NPSR1 Q6W5P4 2/20 0.64
RAB9A P51151 3/20 0.61
HSP90AA1 P07900 2/20 0.61
NPC1 O15118 2/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
CA12 O43570 4/20 0.58
CA1 P00915 4/20 0.58
CA2 P00918 4/20 0.58
CA9 Q16790 4/20 0.58
MAPK1 P28482 1/20 0.58
AMY1A P0DUB6 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57
DHODH Q02127 1/20 0.57
LMNA P02545 1/20 0.57
HSD17B10 Q99714 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21708021 0.88 MAPT (0.68) MAPTGAAMEN1KMT2ANPSR1
SCHEMBL21708008 0.87 KDM1A (0.67) MAPTGAAMEN1KMT2ANPSR1
SCHEMBL18002737 0.87 MAPT (0.56) MAPTGAAMEN1KMT2ANPSR1
SCHEMBL5041112 0.86 EGFR (0.73) MAPTGAAMEN1KMT2ANPSR1
SCHEMBL10464406 0.86 MAPT (0.65) MAPTGAAMEN1KMT2ANPSR1
SCHEMBL4789312 0.86 SMN1; SMN2 (0.69) MAPTGAAMEN1KMT2ANPSR1
SCHEMBL5035870 0.85 LMNA (0.71) MAPTGAAMEN1KMT2ANPSR1
SCHEMBL21708010 0.85 GAA (0.64) MAPTGAAMEN1KMT2ANPSR1
SCHEMBL525606 0.85 MAOA (0.64) MAPTGAAMEN1KMT2ANPSR1
SCHEMBL20530863 0.83 SMN1; SMN2 (0.72) MAPTGAAMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
WO-2012037349-A2 COMPOUNDS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed
US-4933355-A ALDOSE REDUCTASE INHIBITORS SANKYO COMPANY LIMITED (JP) 1990-06-12 US disclosed
EP-0337819-A1 Thiazole derivatives, their preparation and their use in the treatment of diabetes complications Sankyo Company Limited (JP) 1989-10-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A MAPT 4560/4885GAA 3974/4885MEN1 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.